Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01493271 · ClinicalTrials.gov registry record · Phase 2
A Study of RO5093151 in Patients With Ocular Hypertension Or Open Angle Glaucoma
A Phase 2 study of Hypertension, Glaucoma, Open-Angle, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- Phase 2
- Development phase
- 31
- Enrollment target
- 12
- Study locations
NCT01493271 is a Phase 2 study of Hypertension, Glaucoma, Open-Angle that has completed, run by Hoffmann-La Roche. The registered enrollment target is 31 participants. The trial reports 12 study locations across 4 states.
The verdict
NCT01493271, a Phase 2 study of Hypertension, Glaucoma, Open-Angle, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 31 participants
- Enrollment target
- 12
- Study locations
Study Summary
This randomized, double-blind, placebo-controlled, multi-center study will evaluate the safety and the effect of RO5093151 on intraocular pressure in patients with ocular hypertension or open angle glaucoma. Patients will be randomized to receive oral doses of RO5093151 or placebo twice daily. The anticipated time on study treatment is 7 days with the possibility to extend to 28 days.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG RO5093151
Study Locations (12)
Other
- - Sofia
- - Hradec Králové
- - Litomysi
- - Prague
- - Ústí nad Labem
- - Zlín
- - Budapest
- - Budapest
- - Esztergom
Georgia
- - Morrow
North Carolina
- - High Point
South Carolina
- - Mt. Pleasant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2011-12 |
| Est. Completion | 2012-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01493271
The ClinicalTrials.gov registry entry for NCT01493271 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hypertension, Glaucoma, Open-Angle appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT01493271 reports 12 study locations spanning 4 distinct geographic areas - top geographies include Other, Georgia, North Carolina.
Frequently Asked Questions
What is clinical trial NCT01493271 about?
NCT01493271 is a clinical study titled "A Study of RO5093151 in Patients With Ocular Hypertension Or Open Angle Glaucoma". This randomized, double-blind, placebo-controlled, multi-center study will evaluate the safety and the effect of RO5093151 on intraocular pressure in patients with ocular hypertension or open angle glaucoma. Patients will be randomized to receive oral doses of RO5093151 or placebo twice daily. The a...
What is the current status of trial NCT01493271?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 31 participants. The study started on 2011-12. Estimated completion is 2012-11.
What conditions does trial NCT01493271 study?
This clinical trial studies the following conditions: Hypertension, Glaucoma, Open-Angle.
What interventions are being tested in trial NCT01493271?
The interventions under investigation include: Placebo (DRUG), RO5093151 (DRUG).
Who is sponsoring clinical trial NCT01493271?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01493271 being conducted?
This trial has 12 study locations across Georgia, North Carolina, South Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.